univers coverag
calendar event
medic meet abstract releas edt societi pediatr
radiolog societi investig dermatolog american societi gene
cell therapi bold american associ clinic
endocrinologist updat afirma express atla
first efficaci ibd fall short leav room oral
bottom line first efficaci data inhibitor ulcer coliti uc
present late-break digest diseas week ddw june washington dc
present offer import indic class potenti inflammatori bowel diseas
ibd best-in-class treatment psoriasisincreas skin clearanc
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
compar standard anti-tnf see note risankizumab might realli best
class psoriasi mani case offer better safeti toler dose conveni
well market late-stag clinic drug uc undifferenti anti-tnf
efficaci similar magnitud benefit increas demonstr ibd
believ would lead quick adopt market domin howev full abstract
lilli antibodi mirikizumab show endoscop remiss rate week
induct therapi suggest unlik improv upon standard care
uc patient mirikizumab abstract display classic difficulti ibd drug
develop includ placebo-adjust clinic remiss rate endoscop
remiss lack dose respons data replic phase
believ class unlik competit long-term ibd introduct
biosimilar anti-tnf potenti approv multipl oral immunolog medicin
late-stag develop judgment detriment mp
risankizumab given lead ibd commit pivot trial molecul
posit oral ibd medicin face increas demand
biolog includ fail improv standard care develop
oral inhibitor ibd off-set reduc risankizumab expect
compani potenti beaten market least two oral uc pfizer xeljanz jak
first data uc despit drug alreadi phase trial
bottom line continu see facil select stock pick endeavor in-lin
quarter strong price driven acuiti opinion aid optim commerci
mix chang bad debt account reiter contrarian view op
strong structur buy hold name see weak buy opportun also
increas convict op post beat guidanc rais publicli trade hospit
view see significantli multipl dispers base asset base network
ambulatori asset key driver valuat view healthcar util secular
rebound volum rel line quarter post lower expect industri
survey cost side staf wage pressur off-set cost control especi
mm cost save program tax reform offer tailwind lpnt mp
 op particular toward level play field profit competit servic
line improv access point lead invest higher multipl
ambulatori invest remain mp beat improv uk though
facil perform strongli ytd facil index compar
mco
price solid averag elev acuiti though opinion optim
commerci mix inpati set chang bad debt account could also driver
volum rel line quarter post lower expect industri survey
mix rel stabl report largest commerci adj admiss increas sinc
staf wage pressur remain off-set cost control especi mm
compani expand altern access point thc/uspi best posit
see multipl expans due increas weight higher multipl ambulatori asset
mp remain highli lever progress made reduc leverag
tax reform repres ep tailwind less lever name lpnt
remain mp beat uk busi rebound nice though pressur
like remain nh shift referr local govern us busi report
op pt reiter contrarian view strong structur buy hold name
see weak buy opportun
op pt increas convict post beat guidanc rais
op pt lower ebitda estim pt miss driven weak acut
volum behavior swb bh outpati visit pressur
mp pt report beat nice rebound uk still uk censu headwind
driven nh process chang toward local govern referr persist us volum solid
mp pt provid path near-term default relief propos debt chang
lpnt mp pt lpnt report good quarter ebitda exceed buysid expect
mp pt maintain pt ebitda estim report in-lin quarter
bottom line reiter op rate follow hcpc meet attend
appeal reject perman j-code applic sinuva come away
meet reinforc view seemingli clerical/administr error
get overturned/resolv novemb issu final decis consist
read situat link link last week continu believ sinuva launch key growth
driver come year think initi j-code denial derail near long-
term growth trajectori sinuva way -- -especi given physician alreadi get reimburs
unlist j-code think consensu estim prove achiev
like beatabl
dragen acquisit highlight need speed sequenc volum rise
bottom line announc today acquir edico genom dragen platform
edico dragen platform bioinformat solut provid faster data
analysi whole human genom exom smaller project -- via acceler comput
hardwar see posit despit competit fpga field programm gate
array gpu graphic process faster code -- see take anoth step ensur
data analysi hold back progress enorm data gener novaseq
platform around world financi impact alreadi built guid get
edico employe acquisit
recap ceo transit surpris consist pipelin
outperform market cap price price target methodolog dcf
discount rate termin growth rate
bottom line midst manag transit resign presid
ceo jose carlo jc gutierrez-ramo compani expand pipelin use
synthet biotic technolog look new ceo late stage clinic commerci
experi compani reiter program track updat model reflect
financi result end cash cash equival ep loss
per share reiter op pt
revenu mm ep present valu includ estim
model updat convert note
bottom line updat model account convert debt issuanc
announc yesterday note carri rate matur note dilut if/when
note convert consider estim share vs dilut share
count share estim new quarterli interest expens assum option
addit note pick quarter impact lower
ep estim ep estim drop believ
vocera plan use proce net intern invest also like
note year sinc compani acquir extens healthcar
non-gaap ep ep exclud non-cash interest merger cost stock comp amort
trump-azar puls call drug price blueprint limit current hh
puls call recap continu action like remov overhang
may speech point bigger immedi action drug price
hr takeaway cabana unlik chang af practic dd growth
kol discuss mirvetuximab ahead multipl data readout
dcf analysi revenu multipl dr tgr
valu micro-dystrophin program micro pt
jame woy formerli hnt appoint evp health servic
recap pipelin track safeti updat asco
blend discount sale multipl analysi dcf w/ discount rate termin growth rate
 methodolog ep
may bold ph i/ii x-link myotubular myopathy/xlmtm
audent expect announc updat phase i/ii aspiro data
phase i/ii valen data american societi gene cell therapi
confer may
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
may dova pdufa avathombopag thrombocytopenia chronic liver
fda accept avatrombopag nda prioriti review treatment
thrombocytopenia patient chronic liver diseas cld schedul undergo
presum regul valid dova high degre confid
approv applic basi trial well studi
conduct indic
compani plan immedi launch june approv begun hire
key sale staff includ head us sale deep experi liver diseas drug
dova also remain track complet regulatori submiss ema approv
indic
addit cld indic dova explor label expans opportun broader
pre-surgeri popul thrombocytopenia patient chemotherapy-induc
dova believ opportun tripl size avatrombopag address market
may pdufa peg-pal pegvalias phenylketonuria pku
management remain optimist posit outcom fda convey
peg-pal pku shown lower blood phenylalanin amino acid accumul
pt phase studi
think neurocognit data requir fda registr base
discuss agenc
initi induction/titr phase like translat lower revenu per patient
management note meaning reduct phe consequ well ast
adult pt popul could lead attract market opportun almost sale
price releas upon approv management guid modest premium
ahead may pdufa management appear cautiou potenti launch
highlight lower dose use initi lower revenu per pt pegvalias
revenu may limit downsid impact revenu guidanc
yet pku clinic alreadi experienc pegvalias via clinic trial initi
physician pt feedback presum could help investor better project pku
june american societi clinic oncolog -- link titl note
earlier present interim clinic data phase ii studi margetuximab
plu mrk keytruda patient advanc line gastric cancer
expand studi enrol addit gastric cancer patient
compani present updat clinic biomark data year june
assign valu probability-weight sale margetuximab
gastroesophag cancer forecast sale
year meet updat patient treat combin
lead candid mirvetuximab soravtansin avastin
result includ data dose-expans cohort -- patient
avastin-na previous receiv avastin
line treatment set avastin-na pt avastin previous gener
median progression-fre surviv mpf chemotherapi well
continu await product approv expect
delay believ ttoo long-term outlook depend approv
convers manag suggest fda approv near june time-fram
believ earli demand propos quarter indic
interest
given expect market clearanc expect ttoo add addit
sale rep order penetr hospit rep today ou
manag indic sale forc focus sell total solut rather
candida view appear fundament chang
remain unconvinc ttoo sale execut would like see
approv follow solid sale pickup soon
expect topic jak inhibitor ph ii top-lin data alopecia areata
aa us studi patient one month durat could demonstr
earli valid topic jak inhibitor approach
also develop topic jak janu kinas inhibitor patchi hair loss
possibl androgenet alopecia aga aka male/femal pattern bald
success would open anoth multi-billion dollar market
compani jak inhibitor program treatment immune-medi hair loss
disord aa core upsid driver model account
even use conserv assumpt believ oral jak inhibitor could achiev peak
annual sale aa alon
ph ii top-lin data australia eyebrow studi patient
next import catalyst alder six month data ph pivot trial
chronic migrain due second quarter
trial expect provid extend durat repeat dose safeti efficaci
month
data expect includ bla eptinezumab need
consist earlier announc data free increas new
advers event increas neutral antibodi
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
continu optimist ahead pdufa given step taken scph
mitig potenti review risk
manag see signific opportun furoscix reduc patient admiss day
hospit acceler patient discharg reduc readmiss rate
continu believ furoscix subcutan administr gain strong earli
adopt hospital-bas event drive iv furosemid use market
iv diuresi iv furosemid
believ furoscix provid strong pharmacoeconom incent move care
high cost hospit set at-hom set
continu see odd success approv forecast
sale sale
initi furoscix heart failur health econom outcom research studi
june akao pdufa plazomicin gram neg infect
decemb akao report posit top-lin data two phase studi epic
expect support registr expect primari driver
commerci adopt
epic recruit patient suspect complic urinari tract infect cuti
demonstr plazomicin statist non-inferior meropenem fda primari
endpoint statist superior three key efficaci measur includ ema
primari outcom test cure
see nich role plazo treatment-refractori cuti expect drug
primari clinic util carbapenem-resist enterobacteriacea support
compel data studi albeit small sampl show
reduct death/seri complic mortal respect rel
activ control
continu project peak sale plazomicin ww us sale
row royalti us sale come base upon trajectori
agn avycaz accord medacorp kol gener major sale
off-label use infect
compani anticip report ph ii proof-of-concept data
management state observ reduct level -- marker glycem control
dose depend
compani anticip observ dose respons biomark reflect
drug mechan action
goal would posit agent line difficult-to-treat patient use
glycem control compani see potenti market appli
probabl success
model gross sale
believ investor expect head ph ii/iii data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
june present updat analysi pivot
cscc studi focus cemiplimab long-term activ durabl suggest
may addit data studi indic meet
fda approv eversens implant cgm diabet
expect secur fda approv eversens continu glucos
monitor cgm believ nearli total address market
us alon
view eversens appeal broad patient popul encompass
type current declin cgm option due high burden therapi
patient also type reason
alreadi receiv approv eversens eversens xl
europ eversens xl launch uk sweden expect
transit eversens xl europ market
regard us product launch current employe us
commerci team -- readi launch eversens upon fda approv --
compani plan doubl team
fda panel vote unanim favor cgm approv march
believ us approv question
near term secur fda approv eversens time dose claim
like next major catalyst stock
current project us eversens sale
near term secur fda approv eversens time dose claim
like next major catalyst stock
luspatercept phase data md beta-thalassemia
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
sourc leerink research compani inform factset price prior day
fda adcom vaccin relat biolog product
hous rep commerc committe opioid legisl mark-up
pdufa dova avatrombopag thrombocytopenia chronic liver diseas
fda adcom joint anesthet analges drug product drug safeti
fda ad\com anesthesiolog respiratori therapi devic
pdufa akao plazomicin complic urinari tract infect bloodstream
medcac panel procedur volum requir hospit heart team
member begin maintain transcathet aortic valv replac
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
societi pediatr radiolog
abstract releas edt
societi investig dermatolog
american societi gene cell therapi bold
american associ clinic endocrinologist updat afirma
societi neurolog surgeon
world feder hemophilia link
ph phoenix bardoxolon data renal diseas adpkd lgan link note
european academi allergi clinic immunolog dbvt
american societi clinic psychopharmacolog
american colleg sport medicin
european feder nation associ orthopaed traumatolog
societi imag informat medicin
american societi clinic oncolog adap armo celg
american societi transplant surgeon
american societi neuroradiolog
american societi mass spectrometri
american societi microbiolog
associ profession infect control epidemiolog
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst market
 aducanumab titrat arm bolster evid treatment effect market perform
 ctad medacorp call aducanumab abeta hypothesi
life scienc tool diagnost -- flash fund present posit upsid nih
spend life scienc tool
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt market
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 ttr seri part handicap on-going tafamidi trial fac market
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma praluent show mortal benefit lower take aim highest risk group
biopharma -- flash highlight invokana fda warn puls call modest impact
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
biopharma -- flash highlight invokana fda warn puls call modest impact
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
novob dc -- flash near-unanim vote clear path semaglutid approv
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
io clinic trial updat crossroad effici
 deep dive highlight oncolog focu strategi nash market perform
achn recap increment advanc patent complement progress
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst outperform
biopharma might deton event look like screen pot match-
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 add cscc respons diseas boost /sni partnership
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
 atop dermat still without ped leerink dupix
derm survey
 hiv survey rapid adopt biktarvi challeng outlook
gsk
 initi
moat vs
 insight april nyc hc servic day convict
medic suppli devic survey direct posit
mute hope new indications/improv execut
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
 initi could adenosin inhibit unlock wave i/o
outperform
 come-back stori make survey support opu market
share assumpt outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
 pnh survey-soliri still grow like switch monthli sc best
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
 rubraca posit base survey lower est due payer assist
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leerink leadership seri new product growth acceler stori market
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devices-cardiolog leerink leadership seri target
outlook alpha opportun abound healthcar share
